Notable Labs Ltd
NASDAQ:NTBL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Notable Labs Ltd
Capital Expenditures
Notable Labs Ltd
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Notable Labs Ltd
NASDAQ:NTBL
|
Capital Expenditures
-$80k
|
CAGR 3-Years
43%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Capital Expenditures
-$9.8m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-14%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Capital Expenditures
-$95k
|
CAGR 3-Years
76%
|
CAGR 5-Years
30%
|
CAGR 10-Years
-12%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Capital Expenditures
-$289k
|
CAGR 3-Years
-5%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Capital Expenditures
-$83k
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Capital Expenditures
-$1.9m
|
CAGR 3-Years
-70%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-1%
|
|
Notable Labs Ltd
Glance View
Notable Labs Ltd is a IL-based company operating in Biotechnology industry. Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions. The firm has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The firm's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.
See Also
What is Notable Labs Ltd's Capital Expenditures?
Capital Expenditures
-80k
USD
Based on the financial report for Jun 30, 2024, Notable Labs Ltd's Capital Expenditures amounts to -80k USD.
What is Notable Labs Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
37%
The average annual Capital Expenditures growth rates for Notable Labs Ltd have been 43% over the past three years , 37% over the past five years .
